You are on page 1of 2

Drug Delivery Platforms Drug Development Expertise

A UAMS Developed Technology


EZRAs core business revolves around a unique, mathematicallybased drug delivery technology called the Asymmetrically Controlled Tablet (ACT). EZRAs novel tablet and formulation designs act as a platform technology enabling EZRA to mimic difficult to engineer branded drugs. The design of the intended EZRA generic drug does not infringe on the branded pharmaceuticals patent, and/or drug delivery patent, and concurrently satisfies the FDA requirements for generic equivalence.

Ezra Innovations, LLC

The EZRA Team


Cherng-Ju Kim, Ph.D. Inventor and Drug Delivery Consultant Michael Geranen Chairman Chief Executive Officer Dr. Shirish Shah, Ph.D. Regulatory Affairs Joe Fix, Ph.D. Chief Operations Officer Hugh McTavish, Ph.D., J.D. IP Counsel Joe Bell MBA, J.D. Delivery Consultant

Ezra Innovations, LLC

EZRA Innovations, LLC


Arkansas Bioventures University of Arkansas for Medical Sciences 401 S. Cedar Street Little Rock, AR 72205 Arkansas Bioventures OfficeUAMS Campus Phone: 501-686-6696 Fax: 501-686-8501 E-mail: mgeranen@ezrainnovations.com

A Pharmaceutical Research and Development Company

EZRA Innovations, LLC


Our Vision FDA Regulatory Guidance Advantages of the ACT Technology
Being able to replicate across a spectrum of drug franchises without Infringement to the formulation or the brands technology is a competitive advantage that allows EZRA access to large markets. Being able to provide higher milligram strength dose-loads in a sustained release fashion is a distinct competitive advantage. Pricing of manufacturer on a per pill basis is substantially less than other drug delivery technologies. Being able to control and manipulate the release profiles of several sustained release drug delivery technologies. EZRA has the ability to develop generic versions of branded drugs. EZRAs core business revolves around a unique, mathematically-based drug delivery technology called the Asymmetrically Controlled Tablet (ACT). This technology allows EZRA to develop a number of high barrier-to-entry, generic versions of extended release (oncedaily) drugs. EZRA can compete against the pharmaceuticals expensive brand in generic form because of its unique drug delivery technology assessing a large pre-built market. EZRAs drug delivery technology is flexible in design so that it can be engineered to control and manipulate the release of the targeted chemical compound over a 24-hour period. EZRA follows the generic Abbreviated New Drug Application process. This is a short, well defined process outlined by the FDA which allows for generic drug approval to the brand named drug. The pioneer brand drug has already completed the difficult clinical trial which may have required 7.5 years time and inordinate amounts of money. EZRA simply has to conduct a blood level study comparing the release of EZRAs drug in the body to the brand. For this reason, EZRA can conduct a number of trials for generic drug approval supporting a valuable suite of products.